The CCDI will add much-needed capacity to produce and manufacture small molecule drugs, fortifying Canada’s health system and accelerating the growth of the life sciences industry.

Specifically, the CCDI will equip Alberta to:

  • Build out and equip a new 50,000+ ft² manufacturing facility that will produce critical drugs.
  • Upgrade the 72,000 ft² Biotechnology Business Development Centre (BBDC) to incubate more local companies in the scale-up stage.
  • Produce critical hospital drugs that are high-risk due to market challenges, creating a secure supply of drugs critical to Canadians’ health, and a facility that can be mobilized in the event of a crisis.
  • Propel innovations from researchers across Alberta that will provide life-saving drugs.
  • Create more than 350 jobs in Alberta.
  • Increase API’s ability to support more companies through all phases of drug development, from early drug discovery to clinical trials to manufacturing.
Scientist working in lab

Upgrades to the BBDC

Anticipated completion for the upgrades to API’s existing 72,000 ft² facility is 2024. This will add facilities and equipment including:

  • An additional Good Laboratory Practice (GLP) lab

  • Core facilities and improvements to enable the incubation of life science scale-up companies

  • Small molecule chemical synthesis, capable of producing 200 liter batch sizes of small molecule active pharmaceutical ingredients

New Manufacturing Facility

Anticipated completion and opening for API’s new 50,000+ ft² facility is 2026. This will build out key facilities and equipment including:

  • Sterile/aseptic fill/finish facility, capable of an annual throughput of up to 70M doses

  • Multipurpose robotic filling line for small to medium volumes ranging from 1ml to 100ml; both liquid and powder fill; over 43,000 vials per hour

  • Rotating autoclave for emulsion products

  • 2 to 4 manufacturing suites

  • Cold storage and flash freezer

CCDI News and Updates

See all news

Stay in the know

To get the latest news, announcements, and stories about the CCDI, subscribe to our newsletter below.